Go Pro
→ The $15 Gold Fund That Pays Up to $1,152/Month (From Investors Alley) (Ad)tc pixel Free NAVB Stock Alerts

Navidea Biopharmaceuticals (NAVB) Competitors

Navidea Biopharmaceuticals logo
Compare

NAVB vs. SCPS, SMFL, GNCA, ADTX, and ARDS

Should you buy Navidea Biopharmaceuticals stock or one of its competitors? Navidea Biopharmaceuticals's main competitors and comparable companies include Scopus BioPharma (SCPS), Smart for Life (SMFL), Genocea Biosciences (GNCA), Aditxt (ADTX), and Aridis Pharmaceuticals (ARDS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Navidea Biopharmaceuticals compare to Scopus BioPharma?

Navidea Biopharmaceuticals (NYSE:NAVB) and Scopus BioPharma (NASDAQ:SCPS) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, profitability, dividends, earnings, analyst recommendations and media sentiment.

In the previous week, Navidea Biopharmaceuticals' average media sentiment score of 0.00 equaled Scopus BioPharma'saverage media sentiment score.

Company Overall Sentiment
Navidea Biopharmaceuticals Neutral
Scopus BioPharma Neutral

Company Net Margins Return on Equity Return on Assets
Navidea BiopharmaceuticalsN/A N/A N/A
Scopus BioPharma N/A N/A N/A

Navidea Biopharmaceuticals has a beta of 1.76, indicating that its share price is 76% more volatile than the broader market. Comparatively, Scopus BioPharma has a beta of -0.19, indicating that its share price is 119% less volatile than the broader market.

0.0% of Navidea Biopharmaceuticals shares are held by institutional investors. 43.7% of Navidea Biopharmaceuticals shares are held by company insiders. Comparatively, 5.1% of Scopus BioPharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Scopus BioPharma has lower revenue, but higher earnings than Navidea Biopharmaceuticals.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Navidea Biopharmaceuticals$8.13K0.00-$15.18M-$0.21N/A
Scopus BioPharmaN/AN/A-$11.61MN/AN/A

Summary

Navidea Biopharmaceuticals beats Scopus BioPharma on 4 of the 5 factors compared between the two stocks.

How does Navidea Biopharmaceuticals compare to Smart for Life?

Smart for Life (NASDAQ:SMFL) and Navidea Biopharmaceuticals (NYSE:NAVB) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, risk, earnings, valuation, institutional ownership and media sentiment.

28.4% of Smart for Life shares are held by institutional investors. Comparatively, 0.0% of Navidea Biopharmaceuticals shares are held by institutional investors. 31.7% of Smart for Life shares are held by insiders. Comparatively, 43.7% of Navidea Biopharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Smart for Life has a beta of 15.1, suggesting that its stock price is 1,410% more volatile than the broader market. Comparatively, Navidea Biopharmaceuticals has a beta of 1.76, suggesting that its stock price is 76% more volatile than the broader market.

In the previous week, Smart for Life's average media sentiment score of 0.00 equaled Navidea Biopharmaceuticals'average media sentiment score.

Company Overall Sentiment
Smart for Life Neutral
Navidea Biopharmaceuticals Neutral

Navidea Biopharmaceuticals has lower revenue, but higher earnings than Smart for Life. Smart for Life is trading at a lower price-to-earnings ratio than Navidea Biopharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Smart for Life$11.11M0.00-$22.68M-$14.48N/A
Navidea Biopharmaceuticals$8.13K0.00-$15.18M-$0.21N/A

Company Net Margins Return on Equity Return on Assets
Smart for LifeN/A N/A N/A
Navidea Biopharmaceuticals N/A N/A N/A

Summary

Smart for Life beats Navidea Biopharmaceuticals on 4 of the 7 factors compared between the two stocks.

How does Navidea Biopharmaceuticals compare to Genocea Biosciences?

Navidea Biopharmaceuticals (NYSE:NAVB) and Genocea Biosciences (NASDAQ:GNCA) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, institutional ownership, earnings, profitability, analyst recommendations, dividends, valuation and risk.

Navidea Biopharmaceuticals has a beta of 1.76, suggesting that its share price is 76% more volatile than the broader market. Comparatively, Genocea Biosciences has a beta of 1.61, suggesting that its share price is 61% more volatile than the broader market.

Navidea Biopharmaceuticals has higher earnings, but lower revenue than Genocea Biosciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Navidea Biopharmaceuticals$8.13K0.00-$15.18M-$0.21N/A
Genocea Biosciences$1.91M0.00-$33.20M-$0.61N/A

In the previous week, Navidea Biopharmaceuticals' average media sentiment score of 0.00 equaled Genocea Biosciences'average media sentiment score.

Company Overall Sentiment
Navidea Biopharmaceuticals Neutral
Genocea Biosciences Neutral

0.0% of Navidea Biopharmaceuticals shares are owned by institutional investors. Comparatively, 0.6% of Genocea Biosciences shares are owned by institutional investors. 43.7% of Navidea Biopharmaceuticals shares are owned by company insiders. Comparatively, 1.6% of Genocea Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Navidea Biopharmaceuticals' return on equity of 0.00% beat Genocea Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Navidea BiopharmaceuticalsN/A N/A N/A
Genocea Biosciences N/A -182.88%-62.76%

Summary

Navidea Biopharmaceuticals beats Genocea Biosciences on 6 of the 9 factors compared between the two stocks.

How does Navidea Biopharmaceuticals compare to Aditxt?

Navidea Biopharmaceuticals (NYSE:NAVB) and Aditxt (NASDAQ:ADTX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, dividends, risk, institutional ownership, analyst recommendations, media sentiment, earnings and profitability.

Navidea Biopharmaceuticals has a beta of 1.76, suggesting that its stock price is 76% more volatile than the broader market. Comparatively, Aditxt has a beta of 0.95, suggesting that its stock price is 5% less volatile than the broader market.

In the previous week, Navidea Biopharmaceuticals' average media sentiment score of 0.00 equaled Aditxt'saverage media sentiment score.

Company Overall Sentiment
Navidea Biopharmaceuticals Neutral
Aditxt Neutral

Navidea Biopharmaceuticals has a net margin of 0.00% compared to Aditxt's net margin of -360,152.50%. Navidea Biopharmaceuticals' return on equity of 0.00% beat Aditxt's return on equity.

Company Net Margins Return on Equity Return on Assets
Navidea BiopharmaceuticalsN/A N/A N/A
Aditxt -360,152.50%-374.60%-105.93%

0.0% of Navidea Biopharmaceuticals shares are held by institutional investors. Comparatively, 15.5% of Aditxt shares are held by institutional investors. 43.7% of Navidea Biopharmaceuticals shares are held by company insiders. Comparatively, 0.0% of Aditxt shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Given Navidea Biopharmaceuticals' higher possible upside, equities analysts plainly believe Navidea Biopharmaceuticals is more favorable than Aditxt.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Navidea Biopharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Aditxt
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Navidea Biopharmaceuticals has higher earnings, but lower revenue than Aditxt. Aditxt is trading at a lower price-to-earnings ratio than Navidea Biopharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Navidea Biopharmaceuticals$8.13K0.00-$15.18M-$0.21N/A
Aditxt$14.34K0.39-$41.71M-$100.79 thousandN/A

Summary

Navidea Biopharmaceuticals beats Aditxt on 8 of the 12 factors compared between the two stocks.

How does Navidea Biopharmaceuticals compare to Aridis Pharmaceuticals?

Aridis Pharmaceuticals (NASDAQ:ARDS) and Navidea Biopharmaceuticals (NYSE:NAVB) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, earnings, risk, valuation, institutional ownership and profitability.

9.6% of Aridis Pharmaceuticals shares are held by institutional investors. Comparatively, 0.0% of Navidea Biopharmaceuticals shares are held by institutional investors. 5.5% of Aridis Pharmaceuticals shares are held by insiders. Comparatively, 43.7% of Navidea Biopharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Aridis Pharmaceuticals had 1 more articles in the media than Navidea Biopharmaceuticals. MarketBeat recorded 1 mentions for Aridis Pharmaceuticals and 0 mentions for Navidea Biopharmaceuticals. Aridis Pharmaceuticals' average media sentiment score of 0.00 equaled Navidea Biopharmaceuticals'average media sentiment score.

Company Overall Sentiment
Aridis Pharmaceuticals Neutral
Navidea Biopharmaceuticals Neutral

Aridis Pharmaceuticals has a beta of 49.66, meaning that its stock price is 4,866% more volatile than the broader market. Comparatively, Navidea Biopharmaceuticals has a beta of 1.76, meaning that its stock price is 76% more volatile than the broader market.

Company Net Margins Return on Equity Return on Assets
Aridis PharmaceuticalsN/A N/A N/A
Navidea Biopharmaceuticals N/A N/A N/A

Navidea Biopharmaceuticals has higher revenue and earnings than Aridis Pharmaceuticals. Navidea Biopharmaceuticals is trading at a lower price-to-earnings ratio than Aridis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aridis PharmaceuticalsN/AN/A-$30.37M$0.310.00
Navidea Biopharmaceuticals$8.13K0.00-$15.18M-$0.21N/A

Summary

Aridis Pharmaceuticals beats Navidea Biopharmaceuticals on 5 of the 8 factors compared between the two stocks.

Get Navidea Biopharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for NAVB and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NAVB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NAVB vs. The Competition

Export
MetricNavidea BiopharmaceuticalsPharmaceuticals IndustryHealthcare SectorNYSE Exchange
Market Cap$10K$12.25B$7.26B$23.50B
Dividend YieldN/A2.59%2.53%3.73%
P/E Ratio0.00787.27273.2929.39
Price / SalesN/A754.88623.6720.98
Price / CashN/A94.8077.8232.15
Price / BookN/A12.3312.927.63
Net Income-$15.18M$2.82B$3.47B$1.07B

Navidea Biopharmaceuticals Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NAVB
Navidea Biopharmaceuticals
N/AN/AN/AN/A$10K$8.13KN/A10
SCPS
Scopus BioPharma
N/A$0.00
flat		N/AN/A$17KN/AN/A9
SMFL
Smart for Life
N/A$0.00
flat		N/A-92.6%$14K$11.11MN/A110
GNCA
Genocea Biosciences
N/AN/AN/AN/A$6K$1.91MN/A70
ADTX
Aditxt
0.174 of 5 stars		$0.01
+5.5%		N/A-100.0%$5K$14.34KN/A60

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NYSE:NAVB) was last updated on 9/4/2026 by MarketBeat.com Staff.
From Our Partners
The 2026 beginners Guide to Gold IRAs
Gold trades near record highs while silver just topped $81 an ounce for the first time ever. Thousands of A...
Goldco Direct, LLC | Sponsoredtc pixel
A Simple Guide to Options Trading While It's Still Free
A free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...
True Market Insiders | Sponsoredtc pixel
Are you leaving Social Security money on the table?
Most retirement plans still have gaps in them... The quiet ones that don't show up until it's too late to fix....
Money Pickle | Sponsoredtc pixel
How Long Does $2.5M Last in Retirement?
Having $2.5 million saved puts you ahead of most Americans, but how long it lasts depends on the decisions you...
SmartAsset | Sponsoredtc pixel
Before Anthropic becomes impossible to ignore...
Riot Platforms just struck a 20-year, 191-megawatt data-center agreement tied to Anthropic, reportedly worth 9...
The Oxford Club | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Rickards Predicts: Trump to buy tiny $2 stock?
Jim Rickards believes the Trump administration is about to take a direct stake in a $2 stock sitting on the la...
Paradigm Press | Sponsoredtc pixel
Major Buy Alert Issued for September 30th
Keith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...
TradeSmith | Sponsoredtc pixel